Back to Search Start Over

Quality of life should be the primary outcome for disease modifying therapy trials in MS-No.

Authors :
Strijbis E
Koch MW
de Jong BA
Source :
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2023 Aug; Vol. 29 (9), pp. 1066-1067. Date of Electronic Publication: 2023 Jul 25.
Publication Year :
2023

Subjects

Subjects :
Humans
Quality of Life
Immunosuppressive Agents
Multiple Sclerosis, Relapsing-Remitting
Multiple Sclerosis drug therapy

Details

Language :
English
ISSN :
1477-0970
Volume :
29
Issue :
9
Database :
MEDLINE
Journal :
Multiple sclerosis (Houndmills, Basingstoke, England)
Publication Type :
Academic Journal
Accession number :
37489564
Full Text :
https://doi.org/10.1177/13524585231182708
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details